All In Biotech

Drug Trial Radar · NCT06665997

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

65

Planned (sponsor's estimate)

Start

Jun 26, 2025

Primary completion

Jul 31, 2028

Study completion Jul 31, 2028

Sponsor

Lead sponsor
University of PennsylvaniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); Emory University; Children's Hospital of Philadelphia
First posted
Oct 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is being conducted to see if using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain experienced by women with sickle cell disease. Participants in this study will be adult women with sickle cell disease who regularly experience sickle cell pain. They will complete a 3-month "baseline "with no use of hormonal contraception, and then a 3-month follow-up after receiving an injection of Depo-Provera. Participants will complete 6 to 7 in-person visits with a urine pregnancy test, blood draw, and surveys, as well as complete remote weekly surveys and monthly home pregnancy tests.

Conditions

  • Sickle Cell Disease (SCD)
  • Vaso-Occlusive Pain Episode in Sickle Cell Disease

Interventions

  • Depot medroxyprogesterone acetate (DMPA)Drug

    150mg dose intramuscular administration of depot medroxyprogesterone acetate (DMPA) injectable suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of acute vaso-occlusive episodesTime frame: 6 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Emory University

    Atlanta, Georgia · Not yet recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.